Search research articles
Contact Us
Filters
Showing results (271-280 of 286) with videos related to
Page
of 29
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019
P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 17, 2024
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Susan M Swetter, Douglas Johnson, Mark R Albertini, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature
|
March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
The Lancet. Oncology
|
July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Rodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Marie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 286) with videos related to
Sort By:
Page
of 29
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019
P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 17, 2024
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Susan M Swetter, Douglas Johnson, Mark R Albertini, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature
|
March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
The Lancet. Oncology
|
July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Rodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Marie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.
Page
of 29